Rekvina Laboratories share price
BSE: 526075Pharmaceuticals & BiotechnologySmall Cap
Rekvina Laboratories Ltd · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 1993
Last close ₹60.66up ₹2.60 (4.48%)
Share price at the BSE close on 27 Oct 2026. Previous close ₹58.06.
27 Oct: open ₹60.80, high ₹60.96, low ₹55.20
- Under BSE's graded surveillance, stage 0, on the list for 26 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67 Cr4,235th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −139.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,601
Results
Standalone; ₹ crore.Rekvina Laboratories quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.67 Crdown 7.61%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹0.12 CrQuarter to Mar 2026: −₹0.06 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- −18.0%
Revenue by quarter
Peak revenue ₹0.72 Cr, quarter to Mar 2026; lowest ₹0.00 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 8 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.35 | 0.72 | 0.67 |
| Net profit | −0.07 | −0.02 | −0.04 | −0.04 | −0.03 | −0.12 | −0.06 | −0.12 |
| Net margin | – | – | – | – | −17.8% | −35.9% | −8.4% | −18.0% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. Under it, revenue in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹1.27 CrYear to Mar 2025: ₹0.00 Cr
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹0.25 CrYear to Mar 2025: −₹0.14 Cr
- Net margin
- −20.1%
Revenue by year
Peak revenue ₹1.27 Cr, year to Mar 2026; lowest ₹0.00 Cr, year to Mar 2019
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 9 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.27 |
| Net profit | −0.02 | −0.08 | −0.25 | 0.00 | −0.06 | −0.08 | 0.00 | −0.02 | −0.14 | −0.25 |
| Net margin | −67.9% | −421.1% | – | – | – | – | – | – | – | −20.1% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, OPERATING SEGMENT, which carries all its revenue.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Rekvina Laboratories insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 4 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Rekvina Laboratories competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Rekvina Laboratories in market cap.Healthcare companies
Rekvina Laboratories is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Shelter PharmaSHELTER | 72 | 7.98 | 0.94 | +44.4% | +24.7% | 15.1% | – | 0.00% |
 Source Natural Foods & Herbal SupplSOURCENTRL | 71 | 18.85 | 2.75 | +63.1% | +20.6% | 15.6% | 16.7% | 0.00% |
 Vineet LaboratoriesVINEETLAB | 71 | 17.73 | 1.55 | +6.4% | – | 13.2% | 8.8% | 0.00% |
 Sunil HealthcareSUNLOC | 68 | 19.00 | 0.97 | −0.6% | +1,851.4% | 5.2% | 4.9% | 0.00% |
 Onyx BiotecONYX | 66 | – | 1.19 | +12.1% | −104.3% | −0.4% | – | 0.00% |
 Zenith DrugsZENITHDRUG | 65 | 16.38 | 0.88 | +28.4% | −44.9% | 5.5% | – | 0.00% |
 PhaarmasiaPHRMASI | 57 | 3.21 | 2.56 | +111.8% | – | 114.5% | 7.1% | 0.00% |
 Biofil Chemicals & PharmaceuticalsBIOFILCHEM | 49 | 100.58 | 2.26 | +9.3% | −82.7% | 2.4% | 2.1% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Rekvina Laboratories announcements
Oct 2026
Sep 2026
29 Sep · Meeting
29 Sep · Meeting
23 Sep · Announcement under Regulation 30 (LODR)-Change in Registered Office Address
Rekvina Laboratories share price by year
Each calendar year to 2021.Rekvina Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2021 | 4.50 | +7.9% | 4.50 | 3.60 |
| 2020 | 4.17 | −3.0% | 4.45 | 4.02 |
| 2019 | 4.30 | −15.7% | 5.30 | 4.30 |
| 2018 | 5.10 | −7.3% | 5.25 | 5.10 |
| 2017 | 5.50 | −20.6% | 7.00 | 4.27 |
| 2016 | 6.93 | −2.9% | 7.29 | 3.99 |
| 2015 | 7.14 | −51.8% | 15.00 | 6.80 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 1 Mar 2021. 2019 is from its first session, 22 Jan 2019. The close is the year's last trade for 2021 (13 Dec 2021), 2020 (11 Mar 2020), 2018 (26 Nov 2018) and 2017 (30 Nov 2017).
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 26 Oct 2026 | 58.00 | 58.10 | 52.58 | 58.06 | 55.50 | 14,988 |
| 23 Oct 2026 | 60.99 | 60.99 | 55.34 | 55.34 | 56.38 | 1,921 |
| 22 Oct 2026 | 58.14 | 58.25 | 58.14 | 58.25 | 58.21 | 1,326 |
| 21 Oct 2026 | 60.40 | 62.50 | 60.30 | 61.20 | 61.06 | 6,491 |
| 19 Oct 2026 | 61.50 | 62.10 | 60.20 | 62.10 | 60.37 | 8,045 |
| 16 Oct 2026 | 59.50 | 61.50 | 56.90 | 61.49 | 58.45 | 9,115 |
| 15 Oct 2026 | 62.28 | 65.07 | 58.89 | 59.89 | 62.60 | 8,880 |
| 14 Oct 2026 | 61.98 | 61.98 | 57.00 | 61.98 | 61.42 | 11,295 |
| 13 Oct 2026 | 59.03 | 59.03 | 59.03 | 59.03 | 59.03 | 1,954 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 13 Jan 2026 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 30 Apr 2014 | Split | 0.5000 | Each share became 2. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- BSE code
- 526075
- ISIN
- INE092O01028
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.rekvinalaboratories.in
- CIN
- L24231GJ1988PLC011458
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1988
- Registered office
- 3rd floor, 5 Laxmi Society, B/h Baroda Heart Institute, Near Haribhakti Colony, Old padra Road, Vadodara 390007, Gujarat
- Share registrar
- Purva Sharegistry (India) Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments